CD40L GVAX

Drug Profile

CD40L GVAX

Alternative Names: Autologous tumour cell-based vaccine; Bystander vaccine; Bystander-based autologous tumour cell vaccine; CD40LGVAX; Dendristim vaccine; GM-CSF/CD40L; GM.CD40L; GM.CD40L bystander vaccine; hCD40L/hGM-CSF

Latest Information Update: 16 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of South Florida
  • Developer H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Cancer vaccines; CD antigens; Cell therapies; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies
  • Mechanism of Action CD40 antigen stimulants; Gene transference; Granulocyte colony stimulating factor stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Lung cancer; Malignant melanoma
  • No development reported Myelodysplastic syndromes

Most Recent Events

  • 25 Jun 2018 H. Lee Moffitt Cancer Center and Research Institute withdraws a phase I/II trial due to funding unavailable for Lung cancer (Late-stage disease, Combination therapy, Inoperable/ Unresectable) in USA (Intradermal) (NCT02466568)
  • 13 Mar 2017 CD40L GVAX is available for licensing as of 13 Mar 2017. http://www.cellbiomedgroup.com/
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in USA (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top